• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Kerin Adelson Discusses Evolution in Physician Response to Quality Care Initiatives

Video

A gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, noted Kerin Adelson, MD, of Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.

Over time, a gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, said Kerin Adelson, MD, associate professor, chief quality officer, and deputy chief medical officer for Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.

Transcript

AJMC®: How has the reception to quality care initiatives among physicians evolved over time?

Dr Adelson: So, I think that there has been a gradual acceptance that data is honest and that we all have to sort of look at the data and incorporate that into evaluation of our practice. I think for many, many years, the doctor knew best, and to some extent may still, but there was initial resistance to imposing practice standards on somebody's individual practice, that they were the advocate for their patient and outside standards may not sort of reflect the doctor-patient relationship or may even get in the way of it.

I think that there is gradual understanding that evidence-based medicine matters, that the data about how we practice is actually relevant to the care that we give and to the cost of care, and that overutilization is both costly and can actually harm the patient experience by increasing the burden of care or the treatment burden on a patient.

So, I think that sort of the sweet spot is the idea that patients don't want to spend all their time in a CAT scanner if they don't need to, and they don't want to spend all their time getting procedures that could be avoided. So, it is understanding that sometimes appropriate utilization will both save money and improve patient experience–where the alignment occursand that is sort of the selling point, I think, for quality initiatives.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Amy S. Paller, MD, Chair of Dermatology, Feinberg School of Medicine, Northwestern University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.